Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bind Therapeutics files for bankruptcy
by Rick Mullin
May 9, 2016
| A version of this story appeared in
Volume 94, Issue 19
Bind Therapeutics, an oncology nanomedicine drug discovery company, and its affiliate Bind Biosciences Security Corp., have filed a reorganization petition in the U.S. Bankruptcy Court for the District of Delaware. CEO Andrew Hirsch says the filing will give the firm time to reorganize while continuing collaborations with Pfizer and AstraZeneca. Financial backers for the firm include David H. Koch’s DHK Investment and Polaris Partners.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X